BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
77.28
-1.82 (-2.30%)
At close: Jan 30, 2026, 4:00 PM EST
77.27
-0.01 (-0.01%)
After-hours: Jan 30, 2026, 4:18 PM EST
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$484,630
Profits / Employee
-$1,091,942
Market Cap
14.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 730 | 174 | 31.29% | 725 | 5 |
| Dec 31, 2023 | 556 | 160 | 40.40% | 550 | 6 |
| Dec 31, 2022 | 396 | -182 | -31.49% | 392 | 4 |
| Dec 31, 2021 | 578 | 182 | 45.96% | 576 | 2 |
| Dec 31, 2020 | 396 | 148 | 59.68% | 385 | 11 |
| Sep 30, 2020 | 369 | 159 | 75.71% | 369 | 0 |
| Jun 30, 2020 | 328 | 143 | 77.30% | 328 | 0 |
| Mar 31, 2020 | 296 | 144 | 94.74% | 296 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Moderna | 5,800 |
| Genmab | 2,681 |
| Incyte | 2,617 |
| Exelixis | 1,147 |
| Ionis Pharmaceuticals | 1,069 |
| Ascendis Pharma | 1,017 |
| Revolution Medicines | 809 |
| Roivant Sciences | 750 |
BBIO News
- 3 days ago - CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - GlobeNewsWire
- 16 days ago - BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - GlobeNewsWire
- 18 days ago - BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript - Seeking Alpha
- 18 days ago - BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 21 days ago - BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript - Seeking Alpha
- 25 days ago - BridgeBio to Participate in the J.P. Morgan Healthcare Conference - GlobeNewsWire